| 81.21 Delayed Data As of Sep 20 |  +3.09 / +3.96%Today’s Change | 57.00 Today|||52-Week Range 89.30 | +27.71% Year-to-Date |
| Merck's Keytruda Combo Gets FDA Nod for Endometrial Carcinoma Sep 18 / Zacks.com - Paid Partner Content | Merck's Keytruda Combination Gets EC Nod for Kidney Cancer Sep 05 / Zacks.com - Paid Partner Content |
| Novartis' Capmatinib Gets Breakthrough Therapy Tag From FDA Sep 06 / Zacks.com - Paid Partner Content |
| Previous close | 78.12 |
| Today’s open | 78.52 |
| Day’s range | 78.37 - 81.64 |
| Volume | 2,206,030 |
| Average volume (3 months) | 1,191,922 |
| Market cap | $16.4B |
| Earnings growth (last year) | -- |
| Earnings growth (this year) | +222.92% |
| Earnings growth (next 5 years) | +41.50% |
| Revenue growth (last year) | +22.50% |
| P/E ratio | 57.2 |
| Price/Sales | 7.29 |
| Price/Book | 8.47 |
| Today’s change | Today’s % change | |
|---|---|---|
| SGENSeattle Genetics Inc | +1.23 | +1.69% |
| MYLMylan NV | 0.00 | 0.00% |
| ALXNAlexion Pharmaceutic... | +0.65 | +0.62% |
| ALNYAlnylam Pharmaceutic... | +1.90 | +2.25% |
| Next reporting date | October 30, 2019 |
| EPS forecast (this quarter) | $0.41 |
| Annual revenue (last year) | $1.9B |
| Annual profit (last year) | $109.5M |
| Net profit margin | 5.82% |
Sector Health Technology |
Industry Biotechnology |
Chairman, President & Chief Executive Officer Hervé Hoppenot |
Chief Financial Officer & Executive Vice President Christiana Stamoulis |
Corporate headquarters Wilmington, Delaware |
